FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029570639> ?p ?o ?g. }

• W2029570639 endingPage "S228" @default.
• W2029570639 startingPage "S227" @default.
• W2029570639 abstract "We examined whether early response/non-response to risperidone according to the Clinical Global Impressions-improvement scale (CGI-I) at 2 weeks could predict subsequent response. This prediction was also applied to olanzapine. We then investigated whether early non-responders (ENRs) to risperidone or olanzapine who switched to the other showed significantly greater improvement, compared with those staying on the initial antipsychotic. We performed a rater-blinded, randomized controlled trial in 18 psychiatric emergency sites. Eligible patients were newly admitted patients with acute schizophrenia. Early response was defined as CGI-I ≤ 3 following 2 weeks of treatment. The primary outcome measure was achievement of remission and ≥ 50% improvement in the Positive and Negative Syndrome Scale at 4 weeks.At 4 weeks, 53% of risperidone early responders (ERs) went into remission, whereas only 9% of ENRs staying on risperidone (n = 11) did (P = 0.016). Similarly, at 4 weeks, 81% of risperidone ERs achieved ≥ 50% response, whereas only 9% of ENRs staying on risperidone achieved ≥ 50% response (P < 0.0001). In contrast, 58% of olanzapine ERs (n = 33) went into remission, whereas 38% of ENRs staying on olanzapine (n = 8) did at 4 weeks (P = 0.44). Similarly, 61% of olanzapine ERs achieved ≥ 50% response, whereas 25% of ENRs staying on olanzapine achieved ≥ 50% response (P = 0.12). The negative likelihood ratio for the prediction of ≥ 50% response at 4 weeks by early response status to risperidone at 2 weeks was 0.057.In newly admitted patients with acute schizophrenia, non-response to risperidone using CGI-I at 2 weeks can predict subsequent response. It looks like there is significant response to olanzapine that doesn't occur until 4 weeks. Thus, clinicians may want to switch to another drug earlier when risperidone is the first drug, and later when olanzapine is the first drug." @default.
• W2029570639 created "2016-06-24" @default.
• W2029570639 creator A5012750874 @default.
• W2029570639 creator A5022055362 @default.
• W2029570639 creator A5025263774 @default.
• W2029570639 date "2004-10-01" @default.
• W2029570639 modified "2023-10-18" @default.
• W2029570639 title "P.1.121 Venlafaxine XR in depressed and anxiouspatients with multiple, unexplained somatic symptoms in primary care" @default.
• W2029570639 doi "https://doi.org/10.1016/s0924-977x(04)80209-8" @default.
• W2029570639 hasPublicationYear "2004" @default.
• W2029570639 type Work @default.
• W2029570639 sameAs 2029570639 @default.
• W2029570639 citedByCount "0" @default.
• W2029570639 crossrefType "journal-article" @default.
• W2029570639 hasAuthorship W2029570639A5012750874 @default.
• W2029570639 hasAuthorship W2029570639A5022055362 @default.
• W2029570639 hasAuthorship W2029570639A5025263774 @default.
• W2029570639 hasConcept C118552586 @default.
• W2029570639 hasConcept C126322002 @default.
• W2029570639 hasConcept C15744967 @default.
• W2029570639 hasConcept C2776412080 @default.
• W2029570639 hasConcept C2776619155 @default.
• W2029570639 hasConcept C2779727114 @default.
• W2029570639 hasConcept C2780057945 @default.
• W2029570639 hasConcept C2780135775 @default.
• W2029570639 hasConcept C2780494398 @default.
• W2029570639 hasConcept C71924100 @default.
• W2029570639 hasConcept C90924648 @default.
• W2029570639 hasConceptScore W2029570639C118552586 @default.
• W2029570639 hasConceptScore W2029570639C126322002 @default.
• W2029570639 hasConceptScore W2029570639C15744967 @default.
• W2029570639 hasConceptScore W2029570639C2776412080 @default.
• W2029570639 hasConceptScore W2029570639C2776619155 @default.
• W2029570639 hasConceptScore W2029570639C2779727114 @default.
• W2029570639 hasConceptScore W2029570639C2780057945 @default.
• W2029570639 hasConceptScore W2029570639C2780135775 @default.
• W2029570639 hasConceptScore W2029570639C2780494398 @default.
• W2029570639 hasConceptScore W2029570639C71924100 @default.
• W2029570639 hasConceptScore W2029570639C90924648 @default.
• W2029570639 hasLocation W20295706391 @default.
• W2029570639 hasOpenAccess W2029570639 @default.
• W2029570639 hasPrimaryLocation W20295706391 @default.
• W2029570639 hasRelatedWork W1975413208 @default.
• W2029570639 hasRelatedWork W2083472099 @default.
• W2029570639 hasRelatedWork W2085728163 @default.
• W2029570639 hasRelatedWork W2141470899 @default.
• W2029570639 hasRelatedWork W2157127087 @default.
• W2029570639 hasRelatedWork W2158720374 @default.
• W2029570639 hasRelatedWork W2170000130 @default.
• W2029570639 hasRelatedWork W2373217907 @default.
• W2029570639 hasRelatedWork W2413580062 @default.
• W2029570639 hasRelatedWork W2996019069 @default.
• W2029570639 hasVolume "14" @default.
• W2029570639 isParatext "false" @default.
• W2029570639 isRetracted "false" @default.
• W2029570639 magId "2029570639" @default.
• W2029570639 workType "article" @default.